Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein.

Moncrieffe H, Ursu S, Holzinger D, Patrick F, Kassoumeri L, Wade A, Roth J, Wedderburn LR.

Rheumatology (Oxford). 2013 Aug;52(8):1467-76. doi: 10.1093/rheumatology/ket152. Epub 2013 Apr 25.

PMID:
23620557
2.

Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?

Foell D, Frosch M, Schulze zur Wiesch A, Vogl T, Sorg C, Roth J.

Ann Rheum Dis. 2004 Feb;63(2):206-8.

3.

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.

Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, ten Cate R, Hoppenreijs EP, Hansmann S, Moncrieffe H, Ursu S, Wedderburn LR, Roth J, Foell D, Wittkowski H.

Ann Rheum Dis. 2012 Jun;71(6):974-80. doi: 10.1136/annrheumdis-2011-200598. Epub 2012 Jan 20.

PMID:
22267331
4.

Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.

Masi L, Ricci L, Zulian F, Del Monte F, Simonini G, Capannini S, De Martino M, Brandi ML, Falcini F.

J Rheumatol. 2009 Oct;36(10):2308-13. doi: 10.3899/jrheum.081156. Epub 2009 Aug 14.

PMID:
19684155
5.

Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.

Patro PS, Singh A, Misra R, Aggarwal A.

J Rheumatol. 2016 Apr;43(4):731-7. doi: 10.3899/jrheum.150998. Epub 2016 Feb 1.

PMID:
26834220
6.

The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.

Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN.

J Rheumatol. 2004 Jan;31(1):179-82.

PMID:
14705239
7.

Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthesitis-related arthritis category of juvenile idiopathic arthritis.

Viswanath V, Myles A, Dayal R, Aggarwal A.

J Rheumatol. 2011 Nov;38(11):2482-7. doi: 10.3899/jrheum.110352. Epub 2011 Sep 1.

PMID:
21885500
8.

Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations.

Becker ML, van Haandel L, Gaedigk R, Lasky A, Hoeltzel M, Stobaugh J, Leeder JS.

Arthritis Rheum. 2010 Jun;62(6):1803-12. doi: 10.1002/art.27434.

9.
11.

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.

Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le Cessie S, Huizinga TW, Ten Cate R, Guchelaar HJ.

Arthritis Rheum. 2009 Jan 15;61(1):46-51. doi: 10.1002/art.24087.

12.

Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I.

Arthritis Rheum. 2000 Aug;43(8):1849-57.

13.

Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis.

Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB, Malleson PN, Cabral DA.

J Rheumatol. 2004 Dec;31(12):2501-6.

PMID:
15570658
14.

Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry.

Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G.

Arthritis Care Res (Hoboken). 2012 Sep;64(9):1349-56. doi: 10.1002/acr.21697.

15.

A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.

Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A; Pediatric Rheumatology International Trials Organization.

Arthritis Rheum. 2004 Jul;50(7):2191-201.

16.

Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study.

Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, Wulffraat N, Wedderburn L, Stanevicha V, Mihaylova D, Harjacek M, Len C, Toppino C, Masi M, Minden K, Saurenmann T, Uziel Y, Vesely R, Apaz MT, Kuester RM, Elorduy MJ, Burgos-Vargas R, Ioseliani M, Magni-Manzoni S, Unsal E, Anton J, Balogh Z, Hagelberg S, Mazur-Zielinska H, Tauber T, Martini A, Foell D; Paediatric Rheumatology International Trials Organization (PRINTO).

Ann Rheum Dis. 2012 Dec;71(12):1991-7. doi: 10.1136/annrheumdis-2012-201329. Epub 2012 Jun 11.

PMID:
22689317
17.

Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital.

de Thurah A, Nørgaard M, Johansen M, Stengaard-Pedersen K.

Scand J Rheumatol. 2010;39(1):19-25. doi: 10.3109/03009740903185987.

PMID:
20132066
18.

Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria.

Niehues T, Horneff G, Michels H, Höck MS, Schuchmann L; Working Groups Pediatric Rheumatology Germany (AGKJR); Pediatric Rheumatology Austria.

Rheumatol Int. 2005 Apr;25(3):169-78. Epub 2005 Feb 2.

PMID:
15688190
19.

Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.

Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, Stanevicha V, Mihaylova D, Ferriani V, Tsakalidou FK, Foeldvari I, Cuttica R, Gonzalez B, Ravelli A, Khubchandani R, Oliveira S, Armbrust W, Garay S, Vojinovic J, Norambuena X, Gamir ML, García-Consuegra J, Lepore L, Susic G, Corona F, Dolezalova P, Pistorio A, Martini A, Ruperto N, Roth J; Paediatric Rheumatology International Trials Organization (PRINTO).

JAMA. 2010 Apr 7;303(13):1266-73. doi: 10.1001/jama.2010.375. Erratum in: JAMA. 2010 May 26;303(20):2034.

PMID:
20371785
20.

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis.

Bulatovic M, Heijstek MW, Van Dijkhuizen EH, Wulffraat NM, Pluijm SM, de Jonge R.

Ann Rheum Dis. 2012 Sep;71(9):1484-9. doi: 10.1136/annrheumdis-2011-200942. Epub 2012 Apr 3. Erratum in: Ann Rheum Dis. 2012 Dec;71(12):2064.

PMID:
22473625

Supplemental Content

Support Center